JP2009516506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009516506A5 JP2009516506A5 JP2008540416A JP2008540416A JP2009516506A5 JP 2009516506 A5 JP2009516506 A5 JP 2009516506A5 JP 2008540416 A JP2008540416 A JP 2008540416A JP 2008540416 A JP2008540416 A JP 2008540416A JP 2009516506 A5 JP2009516506 A5 JP 2009516506A5
- Authority
- JP
- Japan
- Prior art keywords
- integrin
- seq
- humanized anti
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000006495 integrins Human genes 0.000 claims description 101
- 108010044426 integrins Proteins 0.000 claims description 101
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 80
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 108010048623 Collagen Receptors Proteins 0.000 claims 81
- 102000000507 Integrin alpha2 Human genes 0.000 claims 70
- 108010017642 Integrin alpha2beta1 Proteins 0.000 claims 45
- 239000000203 mixture Substances 0.000 claims 20
- 238000000034 method Methods 0.000 claims 19
- 201000010099 disease Diseases 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 239000003446 ligand Substances 0.000 claims 14
- 102000008186 Collagen Human genes 0.000 claims 9
- 108010035532 Collagen Proteins 0.000 claims 9
- 229920001436 collagen Polymers 0.000 claims 9
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 9
- 201000006417 multiple sclerosis Diseases 0.000 claims 8
- 208000003435 Optic Neuritis Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 6
- 208000020431 spinal cord injury Diseases 0.000 claims 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 5
- 102000000905 Cadherin Human genes 0.000 claims 4
- 108050007957 Cadherin Proteins 0.000 claims 4
- 102000004405 Collectins Human genes 0.000 claims 4
- 108090000909 Collectins Proteins 0.000 claims 4
- 102000014447 Complement C1q Human genes 0.000 claims 4
- 108010078043 Complement C1q Proteins 0.000 claims 4
- 102000004237 Decorin Human genes 0.000 claims 4
- 108090000738 Decorin Proteins 0.000 claims 4
- 241000204855 Echovirus E1 Species 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 150000002500 ions Chemical class 0.000 claims 4
- 239000007790 solid phase Substances 0.000 claims 4
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 208000003782 Raynaud disease Diseases 0.000 claims 3
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 3
- 206010039710 Scleroderma Diseases 0.000 claims 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000028709 inflammatory response Effects 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 230000004044 response Effects 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- 230000002008 hemorrhagic effect Effects 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 230000010118 platelet activation Effects 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73830305P | 2005-11-18 | 2005-11-18 | |
| US60/738,303 | 2005-11-18 | ||
| PCT/CA2006/001876 WO2007056858A1 (en) | 2005-11-18 | 2006-11-17 | Anti-alpha2 integrin antibodies and their uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009516506A JP2009516506A (ja) | 2009-04-23 |
| JP2009516506A5 true JP2009516506A5 (https=) | 2010-01-14 |
| JP5184367B2 JP5184367B2 (ja) | 2013-04-17 |
Family
ID=38048251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008540416A Expired - Fee Related JP5184367B2 (ja) | 2005-11-18 | 2006-11-17 | 抗アルファ２インテグリン抗体およびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US7807794B2 (https=) |
| EP (2) | EP3023497A1 (https=) |
| JP (1) | JP5184367B2 (https=) |
| KR (1) | KR101442266B1 (https=) |
| CN (1) | CN101360826B (https=) |
| AP (1) | AP2809A (https=) |
| AU (1) | AU2006315037C1 (https=) |
| CA (1) | CA2629715C (https=) |
| DK (1) | DK1948798T3 (https=) |
| EA (1) | EA016245B9 (https=) |
| ES (1) | ES2541302T3 (https=) |
| HR (1) | HRP20150691T1 (https=) |
| IL (1) | IL191264A (https=) |
| MY (1) | MY147669A (https=) |
| NO (1) | NO20082454L (https=) |
| NZ (1) | NZ568272A (https=) |
| PL (1) | PL1948798T3 (https=) |
| PT (1) | PT1948798E (https=) |
| RS (1) | RS54111B1 (https=) |
| SI (1) | SI1948798T1 (https=) |
| WO (1) | WO2007056858A1 (https=) |
| ZA (1) | ZA200804148B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3023497A1 (en) * | 2005-11-18 | 2016-05-25 | Glenmark Pharmaceuticals S.A. | Anti-alpha2 integrin antibodies and their uses |
| US20080267978A1 (en) * | 2006-08-28 | 2008-10-30 | Mary Zutter | Anti-angiogenic targets for cancer therapy |
| BRPI0910482A2 (pt) | 2008-04-29 | 2019-09-24 | Abbott Lab | imunoglobinas de domínio variável duplo e usos das mesmas |
| PE20100092A1 (es) | 2008-06-03 | 2010-03-12 | Abbott Lab | Inmunoglobulina con dominio variable dual y usos de la misma |
| KR101054725B1 (ko) | 2008-07-31 | 2011-08-05 | 재단법인서울대학교산학협력재단 | 세포외기질 성분을 함유하는 노화조절용 조성물 및 이를이용한 노화세포의 노화조절방법 |
| EA201190002A1 (ru) * | 2008-11-06 | 2012-04-30 | Гленмарк Фармасьютикалс С.А. | Лечение антителами к интегрину альфа-2 |
| EP2406285B1 (en) * | 2009-03-10 | 2016-03-09 | Gene Techno Science Co., Ltd. | Generation, expression and characterization of the humanized k33n monoclonal antibody |
| WO2011085136A2 (en) * | 2010-01-06 | 2011-07-14 | Elan Pharmaceuticals, Inc. | Use of perlecan domain v in treating amyloidogenic disease |
| US8975376B2 (en) * | 2010-02-23 | 2015-03-10 | Sanofi | Anti-alpha2 integrin antibodies and their uses |
| CN102190728B (zh) * | 2010-03-17 | 2014-07-02 | 永卓博济(上海)生物医药技术有限公司 | 一种人源化抗cd20单克隆抗体 |
| WO2011119732A2 (en) * | 2010-03-24 | 2011-09-29 | Stc.Unm | Method for integrin ligand discovery |
| UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| US8735546B2 (en) | 2010-08-03 | 2014-05-27 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| TWI560199B (en) * | 2010-08-31 | 2016-12-01 | Sanofi Sa | Peptide or peptide complex binding to α2 integrin and methods and uses involving the same |
| US9170138B2 (en) * | 2010-10-01 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced microfluidic electromagnetic measurements |
| DK3252076T3 (da) | 2011-01-14 | 2019-12-02 | Univ California | Diagnostisk anvendelse af antistoffer mod ror-1-protein |
| US9683052B2 (en) | 2011-03-25 | 2017-06-20 | Glenmark Pharmaceuticals S.A. | Hetero-dimeric immunoglobulins |
| CA2840175C (en) * | 2011-05-19 | 2021-11-16 | The Regents Of The University Of Michigan | Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation |
| US20150239956A1 (en) * | 2012-06-27 | 2015-08-27 | Asahi Kasei Medical Co., Ltd. | High-affinity antibody and method for manufacturing the same |
| US20160264663A1 (en) * | 2013-10-21 | 2016-09-15 | The Centre For Drug Research And Development | Anti-podocalyxin antibodies and methods of using the same |
| CN109311994B (zh) | 2015-10-01 | 2022-06-07 | 药物研究及发展中心 | 抗足糖萼蛋白抗体及其使用方法 |
| CN112638403A (zh) * | 2018-07-03 | 2021-04-09 | 康泰伦特药物解决方案有限责任公司 | 包括饰胶蛋白聚糖的多功能蛋白质分子及其用途 |
| CN110007628B (zh) * | 2019-04-10 | 2022-02-01 | 深圳市华星光电半导体显示技术有限公司 | Goa电路及显示面板 |
| CN113557246B (zh) * | 2019-07-24 | 2023-09-01 | 韩国基础科学支援研究院 | 靶向αvβ3整联蛋白的单域抗体 |
| WO2021050970A1 (en) * | 2019-09-13 | 2021-03-18 | Rutgers, The State University Of New Jersey | Aav-compatible laminin-linker polymerization proteins |
| CN111088227A (zh) * | 2019-12-31 | 2020-05-01 | 广州航华生物医药科技有限公司 | 一种细胞分离培养液和t细胞分离培养的方法 |
| CN114931665B (zh) * | 2021-12-14 | 2024-09-27 | 广州医科大学 | 六型胶原α2亚基在神经修复产品中的应用 |
| AU2023301621A1 (en) * | 2022-06-27 | 2025-01-02 | Foreseen Biotechnology (Shanghai) Co., Ltd. | Antibody targeting ITGA2 and antibody-drug conjugate comprising the same |
| CN115184517B (zh) * | 2022-06-30 | 2024-08-13 | 广州金域医学检验中心有限公司 | 一种血浆氨基酸的在线衍生化检测方法 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| WO1987000201A1 (en) | 1985-07-05 | 1987-01-15 | Whitehead Institute For Biomedical Research | Epithelial cells expressing foreign genetic material |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US5166320A (en) | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
| US5306620A (en) | 1987-07-08 | 1994-04-26 | The Scripps Research Institute | Antibodies that bind to a ligand-induced binding site on integrin and induce integrin activation |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| EP0378576B1 (en) | 1987-09-11 | 1995-01-18 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
| WO1989005345A1 (en) | 1987-12-11 | 1989-06-15 | Whitehead Institute For Biomedical Research | Genetic modification of endothelial cells |
| JP2917998B2 (ja) | 1988-02-05 | 1999-07-12 | ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ | 修飾された肝細胞およびその用途 |
| AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5196511A (en) | 1989-12-01 | 1993-03-23 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
| US5262520A (en) | 1989-12-01 | 1993-11-16 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| JP3249516B2 (ja) | 1990-10-31 | 2002-01-21 | ソマティクス セラピー コーポレイション | 遺伝子治療のためのレトロウイルスのベクター |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| US6291196B1 (en) * | 1992-01-31 | 2001-09-18 | Research Corporation Technologies, Inc. | Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy |
| US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| ATE218893T1 (de) | 1993-08-12 | 2002-06-15 | Neurotech Sa | Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten |
| US5523209A (en) | 1994-03-14 | 1996-06-04 | The Scripps Research Institute | Methods for identifying inhibitors of integrin activation |
| US5855888A (en) | 1994-04-26 | 1999-01-05 | Kanebo, Ltd. | Drug for the treatment of rheumatoid arthritis |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6780603B1 (en) | 1995-07-21 | 2004-08-24 | Regents Of The University Of Minnesota | Analysis of alpha integrins for the diagnosis of diabetic nephropathy |
| US5858709A (en) | 1996-10-15 | 1999-01-12 | Smithkline Beecham P.L.C. | Fibronectin binding protein B compounds |
| US6025155A (en) | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| US20020160970A1 (en) | 1996-04-10 | 2002-10-31 | Gyula Hadlaczky | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| EP0942931A2 (en) | 1996-11-21 | 1999-09-22 | Cor Therapeutics, Inc. | Modulation of interactions between myosin and integrins |
| US5932421A (en) | 1996-12-06 | 1999-08-03 | The Scripps Research Institute | Methods and cell lines for identification of regulators of integrin activation |
| EP0879602A1 (en) | 1997-05-21 | 1998-11-25 | Rijksuniversiteit te Leiden | A method to increase the survival of transplanted cells |
| US6596276B1 (en) | 1997-09-30 | 2003-07-22 | Beth Israel Deaconess Medical Center | Method for inhibiting tumor angiogenesis in a living subject |
| DE69934420T2 (de) | 1998-10-07 | 2007-09-27 | Lennart Lindbom | Anti-entzündliche alpha2, beta1 integrin-verwandte substanzen oder antikörper |
| US6849425B1 (en) * | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| EP1414491A4 (en) | 2001-07-09 | 2005-07-06 | Elan Pharm Inc | METHOD OF INHIBITING THE TOXICITY OF AMYLOID |
| US7074175B2 (en) | 2001-07-25 | 2006-07-11 | Erik Schroeder Handy | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| US6997863B2 (en) | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| DE10354806A1 (de) | 2003-11-21 | 2005-06-02 | Boehringer Ingelheim Microparts Gmbh | Probenträger |
| WO2006022682A2 (en) | 2004-08-06 | 2006-03-02 | Applera Corporation | Method and compositions for treating diseases targeting cd49b |
| BRPI0518994A2 (pt) * | 2004-12-31 | 2008-12-02 | Biogen Idec Inc | anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas |
| WO2007024921A2 (en) | 2005-08-24 | 2007-03-01 | Cell Matrix | Combination therapies for inhibiting integrin-extracellular matrix interactions |
| EP3023497A1 (en) | 2005-11-18 | 2016-05-25 | Glenmark Pharmaceuticals S.A. | Anti-alpha2 integrin antibodies and their uses |
| US20080267978A1 (en) | 2006-08-28 | 2008-10-30 | Mary Zutter | Anti-angiogenic targets for cancer therapy |
| FI20075258A0 (fi) | 2007-04-17 | 2007-04-17 | Biotie Therapies Corp | Menetelmä integriiniinhibiittorirespondereiden seulomiseksi |
-
2006
- 2006-11-17 EP EP15162049.9A patent/EP3023497A1/en not_active Withdrawn
- 2006-11-17 WO PCT/CA2006/001876 patent/WO2007056858A1/en not_active Ceased
- 2006-11-17 KR KR1020087014770A patent/KR101442266B1/ko not_active Expired - Fee Related
- 2006-11-17 SI SI200631946T patent/SI1948798T1/sl unknown
- 2006-11-17 RS RS20150437A patent/RS54111B1/sr unknown
- 2006-11-17 EA EA200801314A patent/EA016245B9/ru unknown
- 2006-11-17 HR HRP20150691TT patent/HRP20150691T1/hr unknown
- 2006-11-17 PL PL06804739T patent/PL1948798T3/pl unknown
- 2006-11-17 CA CA2629715A patent/CA2629715C/en not_active Expired - Fee Related
- 2006-11-17 EP EP06804739.8A patent/EP1948798B1/en active Active
- 2006-11-17 JP JP2008540416A patent/JP5184367B2/ja not_active Expired - Fee Related
- 2006-11-17 DK DK06804739.8T patent/DK1948798T3/en active
- 2006-11-17 AU AU2006315037A patent/AU2006315037C1/en not_active Ceased
- 2006-11-17 PT PT68047398T patent/PT1948798E/pt unknown
- 2006-11-17 CN CN200680051249.9A patent/CN101360826B/zh not_active Expired - Fee Related
- 2006-11-17 US US11/601,595 patent/US7807794B2/en not_active Expired - Fee Related
- 2006-11-17 NZ NZ568272A patent/NZ568272A/en not_active IP Right Cessation
- 2006-11-17 ES ES06804739.8T patent/ES2541302T3/es active Active
- 2006-11-17 MY MYPI20081636A patent/MY147669A/en unknown
- 2006-11-17 AP AP2008004471A patent/AP2809A/xx active
-
2008
- 2008-05-05 IL IL191264A patent/IL191264A/en active IP Right Grant
- 2008-05-14 ZA ZA2008/04148A patent/ZA200804148B/en unknown
- 2008-05-30 NO NO20082454A patent/NO20082454L/no not_active Application Discontinuation
-
2010
- 2010-08-17 US US12/858,174 patent/US8759009B2/en not_active Expired - Fee Related
-
2014
- 2014-05-19 US US14/281,101 patent/US20140341892A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009516506A5 (https=) | ||
| US12037408B2 (en) | Method of treating a tumor using anti-TfR antibodies | |
| JP6573424B2 (ja) | ヒト抗ｓｏｄ１抗体 | |
| JP6449441B2 (ja) | ＦｃＲｎ特異的ヒト抗体及びこれを含む自己免疫疾患治療用組成物 | |
| CN105037543B (zh) | 治疗性dll4结合蛋白 | |
| KR101976887B1 (ko) | 항-알파 시누클레인 결합 분자 | |
| CN104144947B (zh) | 用于诊断和治疗铁相关病症的组合物和方法 | |
| KR102781727B1 (ko) | 항-알파 시누클레인 항체 | |
| KR102789446B1 (ko) | 항-알파 시누클레인 항체 | |
| CN105392800A (zh) | 抗cxcl1、cxcl7和cxcl8抗体及其应用 | |
| WO2020193644A1 (en) | ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF | |
| PT2328931E (pt) | Anticorpos selectivos anti-hepcidina-25 e utilizações dos mesmos | |
| HRP20150691T1 (hr) | Anti-alfa2 integrin protutijela i njihova uporaba | |
| CN118284623A (zh) | 抗cd161抗体及其用途 | |
| WO2018022479A1 (en) | Anti-hspa5 (grp78) antibodies and uses thereof | |
| WO2016040571A1 (en) | Methods of treating autoimmune disease using a domain antibody directed against cd40l | |
| CN115244085A (zh) | 用于溶酶体贮积病的蛋白质组学筛查 | |
| US20260109763A1 (en) | Anti-pilra antibodies, uses thereof, and related methods and reagents | |
| JP2022540859A (ja) | 新規ｂｓｓｌ抗体 | |
| WO2023283211A2 (en) | Cd21 antibodies and uses thereof | |
| CN120858112A (zh) | 一种靶向ctgf的抗体或其抗原结合片段及其应用 | |
| BR112018000650B1 (pt) | Anticorpos anti-trf e sua utilização no tratamento de transtornos proliferativos e inflamatórios | |
| HK1256088B (en) | Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders |